Nymox Pharmaceutical Corporation Stock price

Equities

NYMXF

BSP733981026

Biotechnology & Medical Research

Market Closed - OTC Markets 12:26:43 2024-03-28 pm EDT 5-day change 1st Jan Change
0.4 USD -4.76% Intraday chart for Nymox Pharmaceutical Corporation 0.00% -32.20%
Sales 2021 - Sales 2022 - Capitalization 29.51M
Net income 2021 -12M Net income 2022 -6M EV / Sales 2021 -
Net cash position 2021 439K Net cash position 2022 1.23M EV / Sales 2022 -
P/E ratio 2021
-8.5 x
P/E ratio 2022
-4.39 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 57.95%
More Fundamentals * Assessed data
Dynamic Chart
Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH CI
Nymox Pharmaceutical Corporation announced that it has received $2 million in funding CI
Nymox Pharmaceutical Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Nymox Pharmaceutical Corporation announced that it expects to receive $2 million in funding CI
Nymox Pharmaceutical Corporation Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results CI
Nymox Pharmaceutical Corporation Appoints Patrick Doody as Vice President, General Counsel and Member of Board of Directors CI
Fed Outlook Weighs on Exchange-Traded Funds, Equity Futures Premarket Thursday MT
Nymox Pharmaceutical Receives Delisting Notice From Nasdaq MT
Nymox Pharmaceutical Corporation(OTCPK:NYMX.F) dropped from NASDAQ Composite Index CI
Nymox Pharmaceutical Corporation Announces Removal of Board of Directors CI
Nymox Pharmaceutical Corporation Announces Termination of Christopher R. Riley as Chief Financial Officer CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell Microcap Index CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell Microcap Growth Index CI
Nymox Pharmaceutical Corporation(NasdaqCM:NYMX) dropped from Russell 3000E Index CI
More news
1 day-4.76%
Current month+8.84%
1 month+3.90%
3 months-31.51%
6 months-27.40%
Current year-32.20%
More quotes
1 week
0.31
Extreme 0.31
0.43
1 month
0.30
Extreme 0.301
0.55
Current year
0.27
Extreme 0.265
0.62
1 year
0.12
Extreme 0.12
1.28
3 years
0.12
Extreme 0.12
2.87
5 years
0.12
Extreme 0.12
4.79
10 years
0.12
Extreme 0.12
5.79
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 95-05-29
Director/Board Member - 23-07-11
Director/Board Member - 23-03-20
Members of the board TitleAgeSince
Director/Board Member 67 06-06-07
Chief Executive Officer 73 95-05-29
Director/Board Member 88 15-06-30
More insiders
Date Price Change Volume
24-03-28 0.4 -4.76% 34,405
24-03-27 0.42 +10.94% 22,815
24-03-26 0.3786 +20.19% 23,132
24-03-25 0.315 -21.25% 17,321
24-03-22 0.4 0.00% 47,825

Delayed Quote OTC Markets, March 28, 2024 at 12:26 pm EDT

More quotes
Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company focused on developing its drug candidate, NX-1207, for treating benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. The Company’s activities and resources have been directed primarily at developing certain pharmaceutical technologies. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (BPH) and for low grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company started two pivotal double-blind placebo-controlled Phase III trials for NX-1207, NX02-0017 and NX02-0018, conducted at investigational sites across the United States with a total enrollment of approximately 1,000 patients.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock
  2. Equities
  3. Stock Nymox Pharmaceutical Corporation - OTC Markets